Investment Opportunities in Spain Radiopharmaceuticals Market
The Spain Radiopharmaceuticals Market growth continues to accelerate as peptide receptor radionuclide therapy with Lutetium-177 DOTATATE expands treatment options for Spanish patients with progressive neuroendocrine tumours. With neuroendocrine neoplasms representing a growing diagnostic category and somatostatin receptor imaging establishing the molecular basis for PRRT patient selection, the...
0 Comentários 0 Compartilhamentos 47 Visualizações 0 Anterior